DEA's Drug Lab Shopping Watchlist: Chem Sellers Beware!
Published Date: 6/4/2025
Notice
Summary
The DEA just updated a special list of chemicals and equipment that can be used to make illegal drugs. If you sell these lab supplies without checking how they’ll be used, you could face fines. This update affects sellers and buyers, so watch for new rules and stay on the right side of the law!
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Civil Penalties for Reckless Distributions
If you sell lab supplies, you can face civil penalties if you distribute a laboratory supply to someone who uses or attempts to use it to make a controlled substance or listed chemical and the distribution was made with reckless disregard for that illegal use.
Updated Special Surveillance List Coverage
The Drug Enforcement Administration published an update to the Special Surveillance List; any chemical, product, material, or equipment on that list is defined as a "laboratory supply" under the Controlled Substances Act.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-10086, Notice of Public Meetings of the Colorado Advisory Committee to the U.S. Commission on Civil Rights
The Colorado Advisory Committee will hold two virtual meetings on June 18 and July 8, 2025, to plan discussions about antisemitism on three Denver college campuses. Students, staff, and community members connected to these schools might see new efforts to understand and address this issue. These meetings are free to join and aim to make campuses safer and more welcoming.
Next: 2025-10088, Idaho Panhandle Resource Advisory Committee
The Idaho Panhandle Resource Advisory Committee is holding public meetings to help decide on projects and funding for local forests in five counties. They also review recreation fees for these forest sites. If you live or play in these areas, your input could shape how the forests are cared for and how much you might pay to enjoy them.